Aspen Aerogels (ASPN) Projected to Post Quarterly Earnings on Thursday

Key Points

• Aspen Aerogels is set to release its Q2 2025 earnings before the market opens on August 7th, with analysts expecting a loss of ($0.07) per share and revenue of $72.53 million.
• The company's last earnings report showed a revenue decline of 16.7% year-over-year, with a net margin of -65.47%.
• Analysts have mixed ratings for the stock, with the average rating being a "Moderate Buy" and a consensus price target of $18.44.

Aspen Aerogels (NYSE:ASPN - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $72.53 million for the quarter. Aspen Aerogels has set its Q2 2025 guidance at -0.130--0.05 EPS.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The construction company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $78.72 million during the quarter, compared to analyst estimates of $82.75 million. Aspen Aerogels had a negative net margin of 65.47% and a positive return on equity of 6.69%. Aspen Aerogels's revenue was down 16.7% on a year-over-year basis. During the same period last year, the firm posted ($0.02) EPS. On average, analysts expect Aspen Aerogels to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aspen Aerogels Stock Performance

Shares of Aspen Aerogels stock traded down $0.05 during midday trading on Friday, hitting $7.61. The company had a trading volume of 2,397,874 shares, compared to its average volume of 1,954,090. The company has a quick ratio of 3.53, a current ratio of 4.22 and a debt-to-equity ratio of 0.40. Aspen Aerogels has a 12-month low of $4.16 and a 12-month high of $33.15. The stock has a market cap of $624.86 million, a price-to-earnings ratio of -2.18 and a beta of 2.65. The company has a fifty day simple moving average of $6.53 and a 200 day simple moving average of $7.29.

Analyst Ratings Changes

A number of research firms have issued reports on ASPN. Oppenheimer lowered shares of Aspen Aerogels from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 8th. Barclays reissued an "equal weight" rating and set a $7.00 target price (down previously from $13.00) on shares of Aspen Aerogels in a report on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $18.44.

Insider Buying and Selling

In related news, CEO Donald R. Young acquired 20,000 shares of the stock in a transaction on Monday, May 12th. The shares were acquired at an average price of $5.35 per share, for a total transaction of $107,000.00. Following the transaction, the chief executive officer owned 550,856 shares in the company, valued at approximately $2,947,079.60. This trade represents a 3.77% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On Aspen Aerogels

Several institutional investors and hedge funds have recently modified their holdings of ASPN. Royal Bank of Canada increased its holdings in Aspen Aerogels by 84.7% in the 1st quarter. Royal Bank of Canada now owns 56,419 shares of the construction company's stock worth $360,000 after acquiring an additional 25,880 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Aspen Aerogels in the first quarter valued at about $960,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Aspen Aerogels during the first quarter worth about $84,000. Goldman Sachs Group Inc. raised its position in shares of Aspen Aerogels by 89.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,274,356 shares of the construction company's stock worth $8,143,000 after purchasing an additional 602,586 shares during the last quarter. Finally, Caxton Associates LLP purchased a new position in Aspen Aerogels in the 1st quarter valued at about $307,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.